Evidence map›Paper›PMID 41112297›Full record

ReviewFrontiers in immunology2025

Chemokines as key mediators in RIPI: pathophysiology and translational potential.

Ling Zhao, Lihua Dong, Xue Hou, Weijia Fu, Jiaying Wei, Wentong Liu, Wei Hou

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ling ZhaoDepartment of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, Jinlin, China.
Lihua DongDepartment of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, Jinlin, China.
Xue HouDepartment of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, Jinlin, China.
Weijia FuDepartment of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, Jinlin, China.
Jiaying WeiDepartment of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, Jinlin, China.
Wentong LiuDepartment of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, Jinlin, China.
Wei HouDepartment of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, Jinlin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation-induced pulmonary injury (RIPI) is a common adverse effect following thoracic radiotherapy (RT), and immune-related responses play a pivotal role in the pathogenesis of RIPI. Chemokines are important components of the human immune system which could modulate inflammatory responses. Their levels fluctuate following radiation. These chemokines recruit relevant immune cells, such as macrophages and lymphocytes, and induce lung inflammatory responses. In addition to early-stage inflammation, chemokines are also associated with radiation-induced pulmonary fibrosis (RIPF) at a late stage and can augment the risk of post-radiation lung metastasis. Because of the correlation between chemokines and RIPI, chemokines may be useful for RIPI diagnosis and treatment. This review aims to summarize the alterations of the levels of different chemokines after radiation, the regulatory mechanisms, and the advancements of research on the diagnosis and treatment of RIPI by chemokines, in order to provide references for the subsequent RIPI research.

Indexed as

ChemokinesPulmonary FibrosisRadiation InjuriesAnimalsBiomarkersHumansTranslational Research, BiomedicalBiomarkersChemokinesbiomarkerchemokinesinflammatory responsesmacrophagesradiation-induced pulmonary injury (RIPI)

Identifiers

PMID41112297
PMCPMC12528057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.